Format

Send to

Choose Destination
J Tissue Eng Regen Med. 2018 Mar;12(3):e1531-e1536. doi: 10.1002/term.2578. Epub 2017 Nov 10.

Recent progress of national banking project on homozygous HLA-typed induced pluripotent stem cells in South Korea.

Author information

1
CiSTEM Laboratory, Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea, Seoul, 137-701, Republic of Korea.
2
Department of Internal Medicine, Seoul St. Mary's Hospital, Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
3
Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
4
Division of Intractable Diseases, Center for Biomedical Sciences, Korea National Institute of Health, Cheongju, Republic of Korea.
5
Division of Rheumatology, Department of Internal Medicine, College of Medicine, Yonsei University, Seoul, Republic of Korea.
6
Catholic Hematopoietic Stem Cell Bank, Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
7
Department of Biomedical Science and CHA Stem Cell Institute, College of Life Science, CHA University, Seongnam, Republic of Korea.
8
Department of Pediatrics, Seoul St. Mary's Hospital, Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Abstract

Induced pluripotent stem cells (iPSCs) can be generated by introducing several factors into mature somatic cells. Banking of iPSCs can lead to wider application for treatment and research. In an economical view, it is important to store cells that can cover a high percentage of the population. Therefore, the use of homozygous human leukocyte antigen-iPSCs (HLA-iPSCs) is thought as a potential candidate for effective iPSC banking system for further clinical use. We screened the database stored in the Catholic Hematopoietic Stem Cell Bank of Korea and sorted the most frequent homozygous HLA types of the South Korean population. Blood cells with the selected homozygous HLA types were obtained and transferred to the GMP facility in the Catholic Institute of Cell Therapy. Cells were reprogrammed to iPSCs inside the facility and went through several quality controls. As a result, a total of 13 homozygous GMP-grade iPSC lines were obtained in the facility. The generated iPSCs showed high pluripotency and normal karyotype after reprogramming. Five HLA-homozygous iPSCs had the type that was included in the top five most frequent HLA types. Homozygous HLA-iPSCs can open a new opportunity for further application of iPSCs in clinical research and therapy.

KEYWORDS:

bone marrow blood cell; cord blood mononuclear cells; good manufacturing practice; human leukocyte antigen; induced pluripotent stem cells; peripheral blood mononuclear cells; stem cell banking

PMID:
28941241
DOI:
10.1002/term.2578

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center